April 28 - Eli Lilly (NYSE:LLY), Pfizer (NYSE:PFE), Amgen (NASDAQ:AMGN), and possibly other pharma companies could lose up to $51 billion annually if U.S. President Donald Trump's proposed 25% tariffs on pharmaceuticals move forward.
Research from the Pharmaceutical Research and Manufacturers of America (PhRMA) cited by Reuters said the costs could ripple to consumers, raising U.S. drug prices by nearly 13%. In 2023, the U.S. imported $203 billion in pharmaceutical products, with about 73% sourced from Europe, highlighting the country's dependence on foreign medicines.
Although the Commerce Department exempted pharma from reciprocal tariffs, it has launched a separate sector investigation. A 21-day public comment window is now open for feedback on the proposed levies. Drugmakers are urging the administration to phase in tariffs gradually or exempt them altogether, citing that about 25% of U.S. pharmaceutical output, worth $101 billion, was exported last year.
Analysts warn that imposing tariffs could squeeze pharmaceutical jobs and provoke retaliatory moves from trading partners, ultimately weighing on American consumers.
This article first appeared on GuruFocus.免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。